- Health Is Wealth
- Posts
- The first smart health connected drug arrives on the market
The first smart health connected drug arrives on the market
[ad_1]
Proteus Digital Health and its partner Otsuka Pharmaceutical, are about to launch a smart health connected drug. It will be the first mass drug to integrate an ingestible sensor. The marketing of a drug incorporating sensors will undoubtedly cause an upheaval in the pharmaceutical industrial world.
The world's first smart health connected drug
After years of research, clinical trials and studies, Proteus Digital, associated with Otsuka Pharmaceutical is about to launch the very first smart health connected drug. A version of the antidepressant, Abilify, incorporating a sensor, is awaiting FDA approval (Food and Drug Administration). The commercialization of a smart health connected drug will undoubtedly have the effect of a "bomb" on the industrial pharmaceutical market.
What uses and solutions does such a drug provide?
Some diseases, especially mental, do not allow the patient to discuss with the doctor about monitoring treatment for the disease. Thanks to the data collected by the ingestible sensor previously inserted in the medication, a doctor will be able, in real time, adjust dosage of prescriptions or change medication to give to his patient, without the latter being able to communicate orally.
"Today, patients with serious mental illnesses struggle to communicate with their healthcare teams about their drug regimen. Yet a change in medication regimen can greatly influence the outcome and progression of the disease. ”
– Dr. William H. Carson, Chief Executive Officer of Otsuka Pharmaceutical
In order to be able to analyze the effects of the drug on the patient, it is not one, but two sensors the patient should use. The first, the ingestible sensor is directly integrated into the same tablet as the medication. The second is printed on the inside of an adhesive patch which allows to measure the models of medications taken and physiological responses. All the data received by the sensors are displayed on the smartphone, then, if the patient gives his consent, to the doctor.
Will patients agree to ingest a sensor?
We can still ask ourselves the question of public reception of the drug. In France, health trackers and "coaches" are widely accepted by the population, however a real reluctance persists with the implantation of NFC sensor under the skin. When will there be a sensor to ingest?
[ad_2]
AB SMART HEALTH health home & BUILDING REVIEW